Top segments and regional performance

Last year, the company generated ‪65.18 B‬ USD, the most of which — ‪65.18 B‬ USD — came from its top-performing segment, Human Pharmaceutical Products, compared to ‪45.04 B‬ USD the previous year. The greatest contribution came from United States, which accounted for ‪43.48 B‬ USD last year, with ‪30.38 B‬ USD the year before.